Aortic valve stenosis: drivers of disease progression and drug targets for therapeutic opportunities

G Pinto, G Fragasso - Expert Opinion on Therapeutic Targets, 2022 - Taylor & Francis
Introduction Recommended therapy for calcific degenerative aortic stenosis (AS) is still
aortic valve replacement (AVR), either transcatheter or surgical, since no conclusive efficacy …

Chronic kidney disease is a key risk factor for aortic stenosis progression

A Candellier, Y Bohbot, A Pasquet… - Nephrology Dialysis …, 2023 - academic.oup.com
Background Rapid progression of aortic stenosis (AS) has been observed in patients
undergoing dialysis, but existing cross-sectional evidence is contradictory in non-dialysis …

Prediction of the individual aortic stenosis progression rate and its association with clinical outcomes

CS Venema, KH van Bergeijk, D Hadjicharalambous… - JACC: Advances, 2024 - jacc.org
Background The progression rate of aortic stenosis differs between patients, complicating
clinical follow-up and management. Objectives This study aimed to identify predictors …

Pre-procedural oral anticoagulant use is associated with cardiovascular events in women after transcatheter aortic valve replacement: an analysis from the WIN-TAVI …

KH van Bergeijk, JJ Wykrzykowska, S Sartori… - International journal of …, 2023 - Elsevier
Background Transcatheter aortic valve implantation (TAVI) has become an accepted
treatment for patients with severe aortic stenosis (AS). Predicting which patients are at risk …

Aktuálny pohľad na arteriálne kalcifikáty.

M MS - Cardiology Letters, 2023 - search.ebscohost.com
Mohamad MS, Maďarič J. Current view: Arterial calcifications. Cardiology Lett. 2023; 32 (5):
328–335 Abstract: Arterial calcifications are ectopic accumulations of mineral deposits in …